CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors

By GlobeNewswire

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is continuing its investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).

Xenon is a clinical-stage drug company developing azetukalner (formerly XEN1101), its lead drug candidate, for neurological and psychiatric disorders, principally focal-onset seizures, major depressive disorder (MDD), and bipolar depression. Azetukalner is a selective Kv7 potassium-channel opener designed to reduce excessive neuronal activity in the brain. In January 2025, Xenon announced the initiation of its Phase 3 X-NOVA2 trial, designed to enroll approximately 450 patients to evaluate a 20-mg dose of azetukalner against placebo for the treatment of MDD.

After the market closed on September 17, 2026, Xenon announced a voluntary pause in new patient enrollment in its ongoing clinical studies in MDD and bipolar depression following an analysis of neuropsychiatric adverse events in those studies. Following this announcement, Xenon’s stock price fell $17.60 per share, or 30.7%, to close at $39.75 on September 18, 2026, on very heavy trading volume.

Investors who suffered losses trading Xenon common stock and would like to discuss the investigation are encouraged to contact Adam Savett at (212) 451-9655 or asavett@wolfpopper.com.

Wolf Popper has recovered billions of dollars for defrauded investors. Courts have repeatedly recognized the firm’s reputation and expertise by appointing it to major roles in securities litigation. For more information about Wolf Popper, please visit www.wolfpopper.com.

May Be Considered Attorney Advertising in Certain Jurisdictions.
Prior Results Do Not Guarantee a Similar Outcome.

Wolf Popper LLP
Adam Savett, Esq.
570 Lexington Avenue
New York, NY 10022
Tel.: (212) 451-9655
Email: asavett@wolfpopper.com


Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.